Virpax Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2018
Selling, General & Admin	6.26	11.82	9.08	7.19	2.9	Upgrade
Research & Development	5.82	5.12	9.26	4.84	1.29	Upgrade
Operating Expenses	12.08	16.94	18.35	12.03	4.2	Upgrade
Operating Income	-12.08	-16.94	-18.35	-12.03	-4.2	Upgrade
Interest Expense	-0.1	-	-	-0.09	-0.15	Upgrade
Other Non Operating Income (Expenses)	0.12	0.5	0.19	0	0	Upgrade
EBT Excluding Unusual Items	-12.07	-16.44	-18.15	-12.12	-4.34	Upgrade
Legal Settlements	-	-	-2	-	-	Upgrade
Other Unusual Items	-	-	-1.5	0.06	-	Upgrade
Pretax Income	-12.07	-15.19	-21.65	-12.06	-4.34	Upgrade
Net Income	-12.07	-15.19	-21.65	-12.06	-4.34	Upgrade
Net Income to Common	-12.07	-15.19	-21.65	-12.06	-4.34	Upgrade
Shares Outstanding (Basic)	0	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	0	0	0	0	0	Upgrade
Shares Change (YoY)	263.24%	0.02%	75.38%	114.88%	6.09%	Upgrade
EPS (Basic)	-70.91	-324.22	-462.22	-451.39	-349.13	Upgrade
EPS (Diluted)	-70.91	-324.22	-462.22	-451.39	-349.13	Upgrade
EBIT	-12.08	-16.94	-18.35	-12.03	-4.2	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.